What is the P/S ratio for Starling Oncology, Inc. (STLN)?

The P/S ratio for STLN stock is 1.12.

Starling Oncology, Inc.(STLN)

Medical - Care Facilities · Cerritos, CA

$6.58+0.28 (+4.44%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

Compare

PS Ratio: 1.12

Name: Starling Oncology, Inc. (STLN) PS Ratio — historical time series
Creator: TGMCharts

Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

Is the P/S ratio high or low?

The P/S ratio of 1.12 is in line with its estimated 1-year average of 1.06, near the high end of its estimated 1-year range (0.84–1.24).

As of 2026-10-06T22:52:50.784Z.

Stored calculation inputs

Calculation as of: 2026-10-06T22:52:50.784Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 657,887,699
TTM revenue · period ending 2026-06-30: 587,244,000

FMP input reference: ad03cc2eaddb42082332b148aee8d6851fa015397d59a0785f41cacae5aa3ea4

P/E Ratio|Gross Margin|Revenue Growth|All Metrics

PS Ratio

STLN PS Ratio Chart

1.12

Current P/S: FMP quote market capitalization / TTM revenue. Historical estimates use price and reported weighted-average shares; daily points use adjusted close × quarterly weighted-average shares / TTM revenue. Historical series through 2026-10-05.

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

STLN PS Ratio Metrics

PS RATIO

1.12

PS RATIO AVG TTM

N/A

PS RATIO AVG 3Y

N/A

PS RATIO AVG 5Y

N/A

PS RATIO AVG 10Y

N/A

PS RATIO AVG 15Y

N/A

PS RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

N/A

CURRENT VS 3Y AVG

N/A

CURRENT VS 5Y AVG

N/A

CURRENT VS 10Y AVG

N/A

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

4.28

median of 578 covered companies

CURRENT VS SECTOR MEDIAN

-73.80%

vs the sector median at left

STLN Competitors' PS Ratio

STLN

Starling Oncology, Inc.

Current

Market Cap

$657.89M

PS Ratio

1.12

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

FDMT

4D Molecular Therapeutics, Inc.

vs STLN

Market Cap

$656.59M

PS Ratio

7.14

TTM Avg

3326.30

3Y Avg

4783.92

5Y Avg

2925.64

ANNX

Annexon, Inc.

vs STLN

Market Cap

$660.29M

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HELP

Helus Pharma Inc.

vs STLN

Market Cap

$666.95M

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MDXG

MiMedx Group, Inc.

vs STLN

Market Cap

$673.41M

PS Ratio

1.90

TTM Avg

1.93

3Y Avg

2.72

5Y Avg

2.45

AURA

Aura Biosciences, Inc.

vs STLN

Market Cap

$638.20M

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

VSTM

Verastem, Inc.

vs STLN

Market Cap

$681.02M

PS Ratio

7.78

TTM Avg

46.70

3Y Avg

54.33

5Y Avg

64.55

SLDB

Solid Biosciences Inc.

vs STLN

Market Cap

$681.27M

PS Ratio

N/A

TTM Avg

7.55

3Y Avg

21.50

5Y Avg

21.50

ZVRA

Zevra Therapeutics, Inc.

vs STLN

Market Cap

$634.30M

PS Ratio

4.66

TTM Avg

6.00

3Y Avg

10.10

5Y Avg

11.53

PRME

Prime Medicine, Inc.

vs STLN

Market Cap

$632.16M

PS Ratio

155.21

TTM Avg

124.66

3Y Avg

326.25

5Y Avg

326.25

NAME	MARKET CAP	PS RATIO	TTM	3Y	5Y
Starling Oncology, Inc. (STLN)	$657.89M	1.12	N/A	N/A	N/A
4D Molecular Therapeutics, Inc. (FDMT)vs ›	$656.59M	7.14	3326.30	4783.92	2925.64
Annexon, Inc. (ANNX)vs ›	$660.29M	N/A	N/A	N/A	N/A
Helus Pharma Inc. (HELP)vs ›	$666.95M	N/A	N/A	N/A	N/A
MiMedx Group, Inc. (MDXG)vs ›	$673.41M	1.90	1.93	2.72	2.45
Aura Biosciences, Inc. (AURA)vs ›	$638.20M	N/A	N/A	N/A	N/A
Verastem, Inc. (VSTM)vs ›	$681.02M	7.78	46.70	54.33	64.55
Solid Biosciences Inc. (SLDB)vs ›	$681.27M	N/A	7.55	21.50	21.50
Zevra Therapeutics, Inc. (ZVRA)vs ›	$634.30M	4.66	6.00	10.10	11.53
Prime Medicine, Inc. (PRME)vs ›	$632.16M	155.21	124.66	326.25	326.25

How this was calculated

Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.

Revenue calculation and filing references
Fiscal period	Revenue	Source
Q3 FY2025Period ended 2025-09-30	$136,564,000	Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-09-30
Q4 FY2025Period ended 2025-12-31	$141,957,000	Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-12-31
Q1 FY2026Period ended 2026-03-31	$147,441,000	Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-31
Q2 FY2026Period ended 2026-06-30	$161,282,000	Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-06-30
TTM revenue	$587,244,000

Current P/S: $657,887,699 market capitalization ÷ $587,244,000 TTM revenue = 1.12x.

Market capitalization source: FMP quote. Quote observed 2026-10-06T20:00:00.000Z. Latest revenue period ended 2026-06-30.

Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.

These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.

P/S vs. estimated history

At 1.12, P/S is above its estimated 1-year median — higher than 75% of readings in its estimated 1-year history.

estimated 1-year low

0.84

median

1.09

estimated 1-year high

1.24

estimated 1-year lowestimated 1-year high

Sales Valuation

P/S Ratio

1.12

Market Cap / Trailing Twelve-Month Revenue

PS Ratio Formula & Definition

PS Ratio = Market Cap / Revenue (TTM)

The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

PS Ratio FAQ

What is the P/S ratio for Starling Oncology, Inc. (STLN)?: The P/S ratio for STLN stock is 1.12.
Is Starling Oncology, Inc.'s P/S ratio high or low?: The P/S ratio of 1.12 is in line with its estimated 1-year average of 1.06, near the high end of its estimated 1-year range (0.84–1.24).

STLN PS Ratio History

DATE	PS RATIO
2026-10-05	1.11
2026-10-02	1.11
2026-10-01	1.09
2026-09-30	1.11
2026-09-29	1.14
2026-09-28	1.16
2026-09-25	1.17
2026-09-24	1.14
2026-09-23	1.20
2026-09-22	1.24
2026-09-21	1.20
2026-09-18	1.22
2026-09-17	1.16
2026-09-16	1.15
2026-09-15	1.12
2026-09-14	1.14
2026-09-11	1.08
2026-09-10	1.09
2026-09-09	1.10
2026-09-08	1.11
2026-09-04	1.04
2026-09-03	1.05
2026-09-02	1.07
2026-09-01	1.04
2026-08-31	1.04
2026-08-28	1.08
2026-08-27	1.11
2026-08-26	1.15
2026-08-25	1.11
2026-08-24	1.08
2026-08-21	1.14
2026-08-20	1.15
2026-08-19	1.17
2026-08-18	1.12
2026-08-17	1.11
2026-08-14	1.13
2026-08-13	1.10
2026-08-12	1.11
2026-08-11	1.09
2026-08-10	1.08
2026-08-07	1.12
2026-08-06	0.88
2026-08-05	0.88
2026-08-04	0.91
2026-08-03	0.90
2026-07-31	0.85
2026-07-30	0.89
2026-07-29	0.84
2026-07-28	0.87
2026-07-27	0.91
2026-07-24	0.87
2026-07-23	0.89
2026-07-22	0.93
2026-07-21	0.95
2026-07-20	0.96
2026-07-17	0.94
2026-07-16	0.92
2026-07-15	0.99
2026-07-14	1.10
2026-07-13	1.10
2026-07-10	1.03
2026-07-09	1.03
2026-07-08	0.99
2026-07-07	1.02

PS Ratio: 1.12

STLN PS Ratio Chart

STLN PS Ratio Metrics

STLN Competitors' PS Ratio

P/S vs. estimated history

Sales Valuation

PS Ratio Formula & Definition

PS Ratio FAQ

STLN PS Ratio History

Related Metrics